QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.019786v1 69/4/1373    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Márquez, N. Articles by Di Marzo, V. Search for Related Content PubMed PubMed Citation Articles by Márquez, N. Articles by Di Marzo, V.

Iodinated N-Acylvanillamines: Potential "Multiple-Target" Anti-Inflammatory Agents Acting via the Inhibition of T-Cell Activation and Antagonism at Vanilloid TRPV1 Channels

Departamento de Biología Celular, Fisiología e Inmunología, Facultad de Medicina, Universidad de Córdoba, Córdoba, Spain (N.M., F.J.C., A.M., E.M.); Endocannabinoid Research Group, Istituto di Cibernetica and Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy (L.D.P., A.S.-M., V.D.M.); and Università degli Studi del Piemonte Orientale, DiSCAFF, Novara, Italy (A.M., G.A.)

Synthetic N-acylvanillamines were designed and developed as metabolically stable compounds with pharmacological potential in analgesia and inflammation because of their interaction with cannabinoid receptors and the vanilloid receptor (TRPV1). Here, we show that arvanil inhibits early events in T-cell receptor (TCR)-mediated T-cell activation, such as calcium mobilization and nuclear factor of activated T-cell activation, and in late events in TCR-mediated activation, such as interleukin (IL)-2 gene transcription, IL-2R expression, and cell-cycle progression. Arvanil also prevents tumor necrosis factor--induced nuclear factor-B (NF-B) activation by direct inhibition of IB degradation, NF-B binding to DNA, and NF-B-dependent transcription. Aromatic iodination meta to the phenolic hydroxyl (on the 6'-carbon atom) converts arvanil and olvanil from TRPV1 agonists into antagonists. However, this structural modification did not affect the immunosuppressive and proapoptotic activity of these compounds. In summary, we described here novel activities of arvanil on T-cell functions and the development of two novel inhibitors of neurogenic inflammation (6'-I-olvanil and 6'-I-arvanil) endowed with a unique combination of TRPV1 antagonistic-, immunosuppressive-, and NF-B-inhibitory properties. Our findings provide new mechanistic insights into the biological activities of N-alkylvanillamines and should foster the synthesis of improved analogs amenable to pharmaceutical development as analgesic and anti-inflammatory agents.

Address correspondence to: Dr. Eduardo Muñoz Blanco, Departamento Biologia Celular, Fisiologia e Inmunologia, Facultad de Medicina de Córdoba, Avda. Menéndez Pidal s/n, 14004 Córdoba, España. E-mail: fi1muble{at}uco.es